⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

October 1, 2024Frontiers in ImmunologyOpen Access

Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study

Yushan Zhao Shu-Wei Wen YaoQing Xue Zhi-Jun Dang ZhiYu Nan Dong Wang Xiao Li Duiping Feng Yi Chen

View Full Paper

Ask AI

Bookmark

Share

Abstract

Comparing the efficacy of transarterial chemoembolization (TACE) combined with lenvatinib plus tislelizumab (TLT) with TACE combined with lenvatinib (TL) for unresectable hepatocellular carcinoma, particularly in determining which patients can benefit more from the TLT treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhao et al. (2024) studied this question.

synapsesocial.com/papers/68e5600ee2b3180350efd863 https://doi.org/10.3389/fimmu.2024.1449663

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma2024 · 4 citations
2Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis2024 · 7 citations
3TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study2024 · 14 citations
4Transarterial Chemoembolization Combined With Lenvatinib in the Treatment of Intermediate-Stage Hepatocellular Carcinoma With Hypovascular Nodules: A Retrospective Cohort StudyCohort Study · 2026
5Effects of Short-Term Lenvatinib Administration Prior to Transarterial Chemoembolization for Hepatocellular Carcinoma2024 · 7 citations